Chronic Spontaneous Urticaria Pipeline

DelveInsight’s Chronic Spontaneous Urticaria pipeline report provides comprehensive coverage of the emerging drugs profiles, including clinical and nonclinical products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.

Key Takeaways from the Chronic Spontaneous Urticaria Pipeline Report

• There are currently 20+ drugs in the Chronic Spontaneous Urticaria pipeline.

• The Chronic Spontaneous Urticaria pipeline consists of therapies in different clinical phase stages, including Dupilumab, Ligelizumab, AK002, Tezepelumab, UB-221, CDX-0159, and others.

• Leading companies actively working to improve the Chronic Spontaneous Urticaria treatment landscape are Regeneron, Novartis, Allakos, Amgen, United BioPharma, Celldex Therapeutics, and others. 

• Novartis announced in January 2021 that the U.S. Food and Drug Administration (FDA) had granted Ligelizumab (QGE031) Breakthrough Therapy designation for Chronic Spontaneous Urticaria (CSU) treatment. 

• Key Chronic Spontaneous Urticaria pipeline therapies in the early stage of development include UB-221 (United BioPharma), CDX-0159 (Celldex Therapeutics), along with others.

Get a detailed analysis of the pipeline landscape @ Chronic Spontaneous Urticaria Pipeline Analysis

Chronic Spontaneous Urticaria: Overview

Chronic Spontaneous Urticaria (CSU) is defined as hives that last at least 6 weeks and occur on the majority of days of the week. CSU is caused by the pathogenic activation of mast cells and basophils, which results in the release of proinflammatory mediators that contribute to the development of urticaria.

Chronic Spontaneous Urticaria Symptoms

Chronic Spontaneous Urticaria symptoms include:

• Hives or wheals are raised or swollen welts on the skin that appear and disappear over the course of 6 weeks.

• Itching that can be severe at times

• Lips, eyelids, or throat swelling (angioedema)

Chronic Spontaneous Urticaria Treatment

The primary goal of Chronic Spontaneous Urticaria treatment is to eliminate symptoms such as pruritus, wheals, and angioedema. H1 antihistamines act as inverse agonists, combining with and stabilising the H1 receptor’s inactive conformation. Omalizumab, an IgG anti-IgE injectable antibody, was approved in 2014 to treat antihistamine-refractory CSU in people aged 12 and up. A plethora of other potential CSU therapeutics are currently being researched.

Chronic Spontaneous Urticaria Pipeline Analysis: Drug Profiles

Ligelizumab: Novartis

Product Description

Ligelizumab (QGE031) is a monoclonal anti-immunoglobulin E (IgE) antibody of the next generation. Ligelizumab is thought to work by inhibiting the IgE/FcRI pathway, which is a significant driver of the inflammatory process in CSU6. 

Phase III

NCT04210843: Novartis launched a multi-centre, double-blind, open-label extension study in April 2020 to assess the efficacy and safety of ligelizumab as retreatment, self-administered therapy, and monotherapy in patients with chronic spontaneous urticaria who completed studies CQGE031C2302, CQGE031C2303, CQGE031C2202, or CQGE031C1301. The goal of this extension study is to determine ligelizumab’s efficacy and safety.

Chronic Spontaneous Urticaria Pipeline Therapies and Key Companies 

• Dupilumab: Regeneron

• Ligelizumab: Novartis

• AK002: Allakos

•  Tezepelumab: Amgen

• UB-221: United BioPharma

• CDX-0159: Celldex Therapeutics

Find out the emerging therapies and companies @ Chronic Spontaneous Urticaria Clinical Trials

Chronic Spontaneous Urticaria Therapeutics Assessment

• By Product Type

• Monotherapy

• Combination Therapy

• By Stage

• Discovery

• Pre-Clinical

• Phase I

• Phase II

• Phase III

• Pre-registration

• By Route of Administration

• Inhalation

• Intravenous

• Oral

• Subcutaneous

• By Molecule Type

• Small Molecule

• Stem Cell Therapy

• Gene Therapy

• Targets

• Immune System

• Multiple Kinase

• By Mechanism of Action

• Protease Inhibitors

• Immunomodulatory

Scope of the Report

Coverage: Global

Chronic Spontaneous Urticaria Key Players: Regeneron, Novartis, Allakos, Amgen, United BioPharma, Celldex Therapeutics, among others

Chronic Spontaneous Urticaria Pipeline Therapies: Dupilumab, Ligelizumab, AK002, Tezepelumab, UB-221, CDX-0159, and others

Table of Contents

Get in touch with our business executive for Healthcare Due Diligence Services

Key questions answered in the Chronic Spontaneous Urticaria Pipeline Report

• What treatments are available for Chronic Spontaneous Urticaria?

• How many pharmaceutical companies are working on Chronic Spontaneous Urticaria treatments?

• Which of these firms’ pharmaceuticals is the most widely used?

• How many does Each company manufacture chronic Spontaneous Urticaria medications?

• How many drugs for Chronic Spontaneous Urticaria are in the early, mid, or late stages of development?

• How many of the currently being developed therapies can be used alone or in combination with other treatments?

• What are the critical collaborations, mergers and acquisitions, and licencing practises in Chronic Spontaneous Urticaria?

Related Reports

Chronic Idiopathic Urticaria Pipeline Insight

Get a comprehensive analysis of Chronic Idiopathic Urticaria pipeline therapies and key companies, including Novartis, Regeneron, Amgen, AstraZeneca, United BioPharma, Celltrion, Celldex Therapeutics, among others.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/